

TABLE OF CONTENT

	Page
GLOSSARY	1
1. INTRODUCTION	3
1.1. Alzheimer's Disease – Introduction	3
1.2. Alzheimer's Disease – Clinical features, diagnosis and treatment	3
1.3. Alzheimer's Disease – Neuropathology	8
1.4. Alzheimer's Disease – Genetics	10
1.5. The pathogenesis of Alzheimer's Disease: A network of hypotheses	10
1.5.1. The amyloid cascade hypothesis	10
1.5.2. The inflammation hypothesis	13
1.5.3. The role of tau and neurofibrillary tangles	13
1.5.4. The role of autophagy	14
1.5.5. AD pathogenesis revisited	14
1.6. The γ -secretase complex	18
1.7. Amyloid precursor protein processing	22
1.7.1. Basics of intraneuronal amyloid precursor protein processing	22
1.7.2. Presenilin-1 conformation and APP processing	24
1.8. Hypotheses and aims of this study	28
2. MATERIAL AND METHODS	31
2.1. Sample preparation for imaging and in vitro experiments	31
2.1.1. Human tissue study: Sample preparation and study design	31
2.1.2. Mouse tissue study: Sample preparation and study design	31
2.1.3. Preparation of primary neuronal cultures for microscopy	32
2.2. In vitro experiments	33
2.2.1. In vitro drug treatment of primary neuronal cultures with oxidizing agents	33
2.2.2. In vitro treatment of primary neuronal cultures with A β species	33
2.2.3. Cell viability assay of described treatment conditions in primary neuronal cultures	34
2.3. Immunohistochemistry and Immunocytochemistry	34
2.4. Fluorescent lifetime imaging microscopy (FLIM): A resonance energy (RET)	35

based assay	
2.5. In vivo FLIM study	39
2.5.1. Cloning of the fluorescent probes	39
2.5.2. Stereotaxic viral injections for intracortical expression of GFP-PS1-RFP	40
2.5.3. Cranial window surgery	41
2.5.4. In vivo multiphoton microscopy	44
2.6. Biochemistry	45
2.6.1. ELISA A β 42/40 quantification	45
2.6.2. Tissue preparation and immunoblotting	45
2.6.3. Immunoblotting	45
2.6.3.1. Immunoblotting for oxidative stress markers	45
2.6.3.2. Dotblotting	46
2.6.3.3. Immunoblotting for markers of macroautophagy	46
2.7. Statistical analysis	46
2.8. Reagents & drugs	48
3. RESULTS	51
3.1. FLIM studies in human and mouse tissue	51
3.1.1. Human cohorts for the study of PS1 in sAD and aging	51
3.1.2. PS1 conformational changes occur in sporadic Alzheimer's disease	54
3.1.3. PS1 conformation correlates with proximity to A β plaques	57
3.1.4. PS1 conformational changes are associated with aging	61
3.1.5. FLIM to assess endogenous PS1 conformation in mouse brain tissue: fAD mutation versus wildtype PS1	65
3.1.6. L166P FAD PS1 mutation affects G-PS1-R conformation in living	67
3.2. In vitro studies	69
3.2.1. Oxidative stress triggers PS1 conformational changes in primary neuronal cultures in-vitro	69
3.2.2. Oxidative stress triggers PS1 conformational changes in vitro and leads to increased amyloidogenic γ -secretase activity	74
3.2.3. Accumulation of reactive oxidative species occurs in parallel to PS1 conformational changes in the Tg2576 mouse brain	75
3.2.4. Stress factors of the microenvironment surrounding amyloid plaques and PS1 conformation: Preliminary evidence for role for A β itself <i>in vitro</i>	77

3.2.5. Appendix to the results section: In brain tissue from aging Tg2576 and littermates, no alterations of macroautophagy was observed despite change in PS1 conformation	78
4. DISCUSSION	81
4.1. PS1 conformation changes in the brain in sAD and during normal aging	81
4.2. Evidence for γ -secretase modulation by multiple aging and AD related stress factors	85
4.3. PS1 conformation and γ -secretase activity: How do the observed FLIM changes translate into meaningful functional consequences and changes in γ -secretase activity?	89
4.4. Limitations of this study and virtues of this approach	90
4.5. Implications for future therapeutics targeting Amyloid- β peptide: Perspective and current challenges	95
4.5.1. Targeting oxidation	95
4.5.2. Targeting A β clearance	96
4.5.3. Targeting A β production	96
4.5.3.1. β -secretase	96
4.5.3.2. γ -secretase	97
4.5.3.3. Lessons learned for future drug therapy: conclusions and summary	100
5. SUMMARY	102
6. REFERENCES	104
7. LIST OF PUBLICATION	126
8. CURRICULUM VITAE	127
9. ACKNOWLEDGMENT	130
10. APPENDIX	132